港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

高瓴概念

476.659

+5.9491.26%

涨家数：39

跌家数：13

平家数：3

市盈率：- -

高：478.864

开：470.381

低：470.357

收：470.710

数据加载中...

总览新闻资讯

智飞生物：佐剂四价流感疫苗进入Ⅰ/Ⅱ期临床试验

荣昌生物：国家药品监督管理局批准注射用维迪西妥单抗用于治疗HER2阳性且存在肝转移的晚期乳腺癌在中国上市

乐普医疗(300003.SZ)控股子公司民为生物MWN109片获药物临床试验批准通知书

啤酒企业财报：高端化维持不变，即时零售提供增量，行业淡季逆袭

荣昌生物(09995)：爱地希®用于治疗HER2阳性且存在肝转移的晚期乳腺癌在中国获批上市

和铂医药-B(02142)5月9日耗资约161.13万港元回购18.8万股

石药集团1类新药SYH2046获FDA批准开展临床试验

新产业(300832.SZ)获得医疗器械注册证

复星医药(02196)附属菌济健康获美国 FDA 药品临床试验批准

美康生物(300439.SZ)取得医疗器械注册证

医疗器械行业开局再度遇冷 IVD板块成为业绩“重灾区” | 2024器械行业年报

新天绿色能源(00956)4月按合并报表口径完成发电量147.78万兆瓦时同比增加16.91%

石药集团(01093)：SYH2046片获美国临床试验批准

石药集团：SYH2046片获美国临床试验批准

即时零售大战前传：互联网健康的十年“三国杀”

华尔街见闻

恒瑞医药(600276.SH)：SHR-1316(sc)注射液获得药物临床试验批准通知书

翰森制药(03692)：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书

翰森制药：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书

翰森制药(03692.HK)阿美乐第四项适应症获发药品注册证书

阿斯达克财经

归创通桥(02190)5月9日斥资95.85万港元回购5万股

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1583/news?page=13"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":476.6587,"timestamp":1747210102277,"preClose":470.7096,"halted":0,"volume":437220430,"delay":0,"changeRate":0.012639,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":5.949097,"latestTime":"05-14 16:00:00","open":470.38052,"high":478.86423,"low":470.3572,"amount":12232526720.5,"amplitude":0.018073,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747272600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1747186200000,1747195200000],[1747198800000,1747209600000]],"pbRate":2.228639,"peRate":21.389986,"turnoverRate":0.003081,"increases":36,"decrements":15,"flats":3,"marketCap":2694470438016,"floatMarketCap":2109049513856},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":478.86423,"amplitude":0.018073,"preClose":470.7096,"low":470.3572,"pbRate":"2.228639","latestPrice":476.6587,"volume":437220430,"delay":0,"open":470.38052,"prevYearClose":446.93042,"prevWeekClose":480.539,"prevMonthClose":473.358,"prevQuarterClose":505.776,"fiveDayClose":479.992,"twentyDayClose":468.236,"sixtyDayClose":464.977,"secType":"PLATE","market":"HK","turnoverRate":0.003081,"peRate":21.389986,"marketCap":2694470438016,"floatMarketCap":2109049513856,"timestamp":1747210102277,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":39,"down":13,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:13,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534488425","title":"智飞生物：佐剂四价流感疫苗进入Ⅰ/Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534488425","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534488425?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 19:41","pubTimestamp":1746790888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0046","BK0077","LU2580892862.HKD","LU2580892789.USD","BK0196","LU1064130708.USD","159646","03347","BK0239","BK1141","BK1583","BK0188","LU1328615791.USD","BK1576","300122","LU1064131003.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2534344488","title":"荣昌生物：国家药品监督管理局批准注射用维迪西妥单抗用于治疗HER2阳性且存在肝转移的晚期乳腺癌在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2534344488","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534344488?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 19:24","pubTimestamp":1746789858,"startTime":"0","endTime":"0","summary":"格隆汇5月9日丨荣昌生物公告，注射用维迪西妥单抗正式获得中国国家药品监督管理局在中国上市的批准，用于治疗HER2阳性且存在肝转移的晚期乳腺癌的患者。维迪西妥单抗组整体安全性良好，未发现新的安全性信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050919241897546ebe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050919241897546ebe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1161","BK1583","BK1574","LU2328871848.SGD","09995"],"gpt_icon":0},{"id":"2534310099","title":"乐普医疗(300003.SZ)控股子公司民为生物MWN109片获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534310099","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534310099?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 19:23","pubTimestamp":1746789835,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗(300003.SZ)公告，公司控股子公司上海民为生物技术有限公司(简称“民为生物”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由民为生物申报的MWN109片临床试验申请获得批准。根据《中华人民共和国药品管理法》及有关规定，经审查，2025年3月3日受理的MWN109片临床试验申请符合药品注册的有关要求，同意本品开展超重或肥胖适应症的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","BK0188","BK0113","BK1141","BK0201","BK0251","BK0028","BK1583","BK0114","03347","300003","BK1576","BK0196"],"gpt_icon":0},{"id":"2534100761","title":"啤酒企业财报：高端化维持不变，即时零售提供增量，行业淡季逆袭","url":"https://stock-news.laohu8.com/highlight/detail?id=2534100761","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534100761?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 19:23","pubTimestamp":1746789828,"startTime":"0","endTime":"0","summary":"伴随着2024年的行业调整结束，主要的啤酒上市企业青岛啤酒、华润啤酒、重庆啤酒、百威亚太、燕京啤酒、珠江啤酒已经交出了2024年度成绩单。从各个酒企的财报中，新京报记者发现，2024年燕京啤酒、珠江啤酒呈现业绩增长状态，高端化依旧是各个企业的主要话题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505093400750634.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505093400750634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1578","LU1720050803.USD","BK1570","LU1794554557.SGD","LU1328615791.USD","LU0359202008.SGD","LU1023057109.AUD","IE0008369823.USD","BK1583","IE0008368742.USD","LU0359201612.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","IE0031814852.USD","BK1510","BK1180","BK1589","00291","BK1521","SG9999006514.SGD","IE00B0169L03.USD","BK1604","80291","IE00B031HY20.USD","CRHKY","IE00BPRC5H50.USD","IE00B29SXG58.USD"],"gpt_icon":0},{"id":"2534408107","title":"荣昌生物(09995)：爱地希®用于治疗HER2阳性且存在肝转移的晚期乳腺癌在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2534408107","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534408107?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 19:18","pubTimestamp":1746789503,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 公布，注射用维迪西妥单抗正式获得中国国家药品监督管理局在中国上市的批准，用于治疗HER2 阳性且存在肝转移的晚期乳腺癌的患者。本适应症获得批准是基于RC48-C006 III期临床研究，详细数据在2024年12月的圣安东尼奥乳腺癌研讨会公布，结果显示：相比拉帕替尼联合卡培他滨组，维迪西妥单抗组显著延长了无进展生存期，疾病进展或死亡风险降低了44%。维迪西妥单抗组整体安全性良好，未发现新的安全性信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","LU1064130708.USD","LU1064131003.USD","BK1161","688331","LU1969619763.USD","BK1583","LU2328871848.SGD","BK1574","LU2148510915.USD","BK0239"],"gpt_icon":0},{"id":"2534078241","title":"和铂医药-B(02142)5月9日耗资约161.13万港元回购18.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2534078241","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534078241?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 19:07","pubTimestamp":1746788848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布，2025年5月9日耗资约161.13万港元回购18.8万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","02142","BK1161"],"gpt_icon":0},{"id":"2534100774","title":"石药集团1类新药SYH2046获FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534100774","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534100774?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 19:01","pubTimestamp":1746788515,"startTime":"0","endTime":"0","summary":"5月9日，石药集团发布公告，宣布其开发的化药1类新药SYH2046片已获得美国食品药品监督管理局批准，可以在美国开展临床试验。该产品也已于2025年4月获得中国国家药品监督管理局的批准，允许在中国进行临床试验。SYH2046片是一款具有完全自主知识产权的全新结构first-in-class小分子药物，主要适应症为急性心肌梗死后心力衰竭。目前，公司已在国内外提交多项该产品的专利申请。文章来源：财中社石药集团1类新药SYH2046获FDA批准开展临床试验","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509191055a6d902d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509191055a6d902d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0140636845.USD","IE0008368742.USD","LU1226287792.SGD","LU0072913022.USD","LU1008478684.HKD","LU1807302812.USD","IE00B031HY20.USD","LU1951186391.HKD","01093","IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK1583","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521","LU1226288253.USD","03347","LU1152091754.HKD","LU1226287875.USD","LU1226288170.HKD","BK1515","LU1960683339.HKD","LU1152091168.USD","IE0008369823.USD","LU0501845795.SGD","BK1141","LU1993786604.SGD","IE00BZ08YT58.USD","LU0326950275.SGD","BK1576","LU0067412154.USD","LU0880133367.SGD","LU1226287529.USD","BK1191","SG9999004220.SGD"],"gpt_icon":0},{"id":"2534104770","title":"新产业(300832.SZ)获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2534104770","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534104770?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:59","pubTimestamp":1746788378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新产业(300832.SZ)公告，公司收到了广东省药品监督管理局颁发的1项《医疗器械注册证》，产品名称为C反应蛋白测定试剂盒(胶乳免疫比浊法)，用于体外定量测定人血清或血浆中C反应蛋白的含量。临床上用于非特异性炎症的辅助诊断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","09996","BK1100","BK1574","BK1583","300832","BK1222","09997","159883"],"gpt_icon":0},{"id":"2534104693","title":"复星医药(02196)附属菌济健康获美国 FDA 药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534104693","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534104693?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:48","pubTimestamp":1746787704,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司上海菌济健康科技有限公司(以下简称“菌济健康”)收到美国 FDA(即美国食品药品监督管理局)关于同意 LBP-ShC4 开展临床试验的批准。菌济健康拟于条件具备后开展 LBP-ShC4 的 I 期临床试验。LBP-ShC4 为集团自主研发的活体生物治疗产品，拟用于治疗雄激素脱发(AGA)。截至 2025 年 4 月，集团现阶段针对 LBP-ShC4 的累计研发投入约为人民币 0.17 亿元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0183","BK0028","03347","BK1141","02196","BK0239","BK0187","BK0188","BK0196","BK0096","BK0012","BK1593","600196","BK1191","BK1515","BK0060","BK1576","BK1583"],"gpt_icon":0},{"id":"2534104896","title":"美康生物(300439.SZ)取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2534104896","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534104896?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:47","pubTimestamp":1746787667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)公告，公司于近日取得了由浙江省药品监督管理局颁发的《中华人民共和国医疗器械注册证(体外诊断试剂)》，产品名称分别为卡马西平质控品(用于人血清或血浆中卡马西平(CBZ)定量测定时的质量控制)及丙戊酸质控品(用于人血清或血浆中丙戊酸(VPA)定量测定时的质量控制)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","09996","BK1222","300439","BK0239","BK1583","159883","BK1100","BK1574","09997","BK0042"],"gpt_icon":0},{"id":"2534101351","title":"医疗器械行业开局再度遇冷 IVD板块成为业绩“重灾区” | 2024器械行业年报","url":"https://stock-news.laohu8.com/highlight/detail?id=2534101351","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534101351?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:39","pubTimestamp":1746787140,"startTime":"0","endTime":"0","summary":"　　2024年，中国医疗器械行业在政策调整、市场需求波动与全球供应链重构的多重挑战中艰难企稳，全年收入增速转正至0.78%，但利润端分化显著。进入2025年，行业开局再度遇冷，Q1营收、归母净利润、扣非净利润同比下滑6.87%、12.17%、17.42%。医疗设备招标滞后、IVD集采冲击及高值耗材需求波动成为主因。　　医疗设备板块呈现深度调整态势，全板块营业收入同比下滑4.1%，归母净利润与扣非归母净利润分别大幅收缩35.5%和38.8%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-05-09/doc-inevyhfv9172518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09997","09996","BK1222","BK1100","BK1583","159883"],"gpt_icon":0},{"id":"2534610679","title":"新天绿色能源(00956)4月按合并报表口径完成发电量147.78万兆瓦时 同比增加16.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534610679","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534610679?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:37","pubTimestamp":1746787026,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新天绿色能源 发布公告，2025年4月，该集团按合并报表口径完成发电量147.78万兆瓦时，同比增加16.91%。截至2025年4月30日，累计完成发电量602.20万兆瓦时，同比增加11.91%。截至2025年4月30日，累计完成输╱售气量219714.10万立方米，同比减少17.09%，其中售气量201505.79万立方米，同比减少14.85%;代输气量18208.30万立方米，同比减少35.78%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00956","BK1594","BK1558","BK1166","BK1583","BK1503"],"gpt_icon":0},{"id":"2534106973","title":"石药集团(01093)：SYH2046片获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106973","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534106973?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:31","pubTimestamp":1746786691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的化药1类新药SYH2046片(该产品)已获得美国食品药品监督管理局批准，可以在美国开展临床试验。该产品是一款具有完全自主知识产权的全新结构first-in-class小分子药物，本次获批的临床试验适应症为急性心肌梗死后心力衰竭。临床前研究表明，该产品可显着改善疾病动物模型的心脏功能并降低心脏不良重构，且具有较高的安全性。目前，本集团已在国内外提交该产品的多项专利申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0326950275.SGD","03347","IE00BZ08YT58.USD","LU1152091168.USD","LU1951186391.HKD","LU1226288170.HKD","LU0140636845.USD","BK1521","IE0008368742.USD","LU1152091754.HKD","LU0067412154.USD","01093","BK1576","BK1515","IE00B031HY20.USD","LU0880133367.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","LU1960683339.HKD","LU1807302812.USD","LU1008478684.HKD","IE00BZ08YR35.GBP","LU1226287529.USD","BK1191","SG9999004220.SGD","IE00B543WZ88.USD","BK1141","IE0008369823.USD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU1993786604.SGD","BK1583","LU0501845795.SGD","LU1226288253.USD"],"gpt_icon":0},{"id":"2534310591","title":"石药集团：SYH2046片获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534310591","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534310591?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:29","pubTimestamp":1746786595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0326950275.SGD","LU1152091168.USD","LU1993786604.SGD","LU0072913022.USD","LU0880133367.SGD","LU1960683339.HKD","BK1583","SG9999004220.SGD","IE0008368742.USD","IE00BZ08YR35.GBP","BK1515","IE00B031HY20.USD","BK1141","LU1226288170.HKD","IE00B543WZ88.USD","LU1226288253.USD","01093","LU1226287792.SGD","LU0140636845.USD","03347","BK1576","LU1226287529.USD","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1951186391.HKD","BK1191","BK1521","LU1226287875.USD","LU1807302812.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU0501845795.SGD","IE0008369823.USD","LU1152091754.HKD","LU0067412154.USD"],"gpt_icon":0},{"id":"2534106420","title":"即时零售大战前传：互联网健康的十年“三国杀”","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106420","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534106420?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:24","pubTimestamp":1746786254,"startTime":"0","endTime":"0","summary":"互要流量","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3746786","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3746786","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0594300179.USD","BK1584","LU0348827113.USD","LU1201861165.SGD","LU1044876610.USD","LU0890818403.SGD","03690","LU1046422090.SGD","LU0128525689.USD","LU1720051108.HKD","LU2242644610.SGD","06618","BK4579","LU0531971595.HKD","86618","LU1808992512.USD","LU0231483743.USD","BK1515","89988","LU1328277881.USD","BK4504","LU0463099449.HKD","LU0819123356.HKD","00241","BK1583","LU2257852520.SGD","LU0140636845.USD","BK4524","LU0871576103.HKD","LU1675838814.USD","ALBmain","LU0700851271.USD","LU0181495838.USD","09939","METmain","LU0315179316.USD","LU0359201885.HKD","MPNGY","HMTD.SI","LU1282651121.HKD","LU0651946864.USD","LU2125910500.SGD","LU0029875118.USD","LU2097828474.EUR","89618","HBBD.SI"],"gpt_icon":1},{"id":"2534177637","title":"恒瑞医药(600276.SH)：SHR-1316(sc)注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177637?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:55","pubTimestamp":1746784534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1316(sc)注射液的《药物临床试验批准通知书》，将于近期开展临床试验。具体为SHR-1316(sc)联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌中的药代动力学、安全性、耐受性及疗效的开放、多中心Ⅰ期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU0405327494.USD","BK1583","03347","LU2488822045.USD","BK0196","BK0188","BK0012","BK1576","LU0405327148.USD","LU1328615791.USD","BK0028","LU2328871848.SGD","LU1969619763.USD","BK0060","BK0239","600276","LU1064131003.USD","LU1064130708.USD","BK1141","LU2148510915.USD"],"gpt_icon":0},{"id":"2534177653","title":"翰森制药(03692)：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177653","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177653?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:55","pubTimestamp":1746784500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，本集团创新药阿美乐®(甲磺酸阿美替尼片)获中国国家药品监督管理局(NMPA)签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌“NSCLC”)患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐®获批的第四项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0},{"id":"2534999483","title":"翰森制药：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534999483","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534999483?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:53","pubTimestamp":1746784413,"startTime":"0","endTime":"0","summary":"格隆汇5月9日丨翰森制药发布公告，集团创新药阿美乐获中国国家药品监督管理局签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21置换突变的成人非小细胞肺癌“NSCLC”）患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1583","03692","BK1191"],"gpt_icon":0},{"id":"2534558177","title":"翰森制药(03692.HK)阿美乐第四项适应症获发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534558177","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534558177?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:50","pubTimestamp":1746784200,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，创新药阿美乐获国家药品监督管理局签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。阿美乐是中国首个原研三代EGFR-TKI创新药，此前已于中国获批三项适应症。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-09 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1438988/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","03692","BK1191","BK1589"],"gpt_icon":0},{"id":"2534171299","title":"归创通桥(02190)5月9日斥资95.85万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2534171299","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534171299?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:37","pubTimestamp":1746783453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2025年5月9日斥资95.85万港元回购股份5万股，每股回购价格为18.86-19.82港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1587","BK1100","02190","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":35,"pageCount":13,"totalSize":693,"code":"91000000","status":"200"}]}}